0
Abstract: Poster Presentations |

PROTECTIVE EFFECT OF ANTITHROMBIN III AGAINST LUNG AND MYOCARDIAL INJURY IN LOWER LIMB ISCHEMIA-REPERFUSION SYNDROME FREE TO VIEW

Neophytos Zambas, MD*; Dimitrios Karamanos, MD; Christos D. Karkos, MD; Apostolos Kamparoudis, MD; Georgios Papageorgiou, MD; Charalambos Spyridis, MD; Ilias Bassagiannis, MD; Thomas S. Gerassimidis, MD
Author and Funding Information

5th Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki, Greece


Chest


Chest. 2009;136(4_MeetingAbstracts):75S-c-76S. doi:10.1378/chest.136.4_MeetingAbstracts.75S-c
Text Size: A A A
Published online

Abstract

PURPOSE:  Restoration of blood flow to an acutely ischemic limb can trigger systemic inflammation. We investigated whether antithrombin III (AT III) exerts a protective action against remote lung and myocardial injury in an experimental animal model of lower limb ischemia-reperfusion.

METHODS:  Ischemia was induced by right lower limb arterial occlusion for 4 hours in 60 male Wistar rats. Animals were divided into those receiving AT III (dose 250mg/kg, Kybernin P; Aventis Behring GmbH) 30 minutes before the reperfusion (group A, n = 30), and those receiving placebo (group B, n = 30). Animals were then sacrificed and lung and myocardial tissue samples were taken at baseline, 30 minutes, and 4 hours after reperfusion. Malondialdehyde (MDA) levels, a compound used as indirect index of oxygen free radicals which play a significant role in the pathogenesis of ischemia-reperfusion syndrome, were estimated in lung and myocardium and the two groups were compared at different time points using the independent sample t-test.

RESULTS:  Animals given AT III had significantly lower lung MDA levels comparing with the placebo group at baseline and at 30 minutes, but not at 4 hours (p = 0.001, p = 0.01 and p = 0.9, respectively) indicating a protective action against remote lung injury early in the reperfusion phase. With regard to myocardial MDA levels, no statistically significant differences existed between the AT-III and placebo groups at baseline, at 30 minutes and at 4 hours (p = 0.07, p = 0.07, and p = 0.2, respectively).

CONCLUSION:  In this experimental animal model, AT III seems to exert a protective effect against remote ischemia-reperfusion injury in the lung tissue but not in the myocardium.

CLINICAL IMPLICATIONS:  AT III may prove to be of clinical benefit in attenuating remote lung injury in ischemia-reperfusion syndrome. Further experimental and clinical studies are warranted.

DISCLOSURE:  Neophytos Zambas, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, November 4, 2009

12:45 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543